Nurix Therapeutics, Inc. NRIX
NASDAQ
| 08/31/2026 | 05/31/2026 | ||||
|---|---|---|---|---|---|
| Revenue | 7,342.93% | 44.64% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 7,342.93% | 44.64% | |||
| Cost of Revenue | -9.58% | 4.18% | |||
| Gross Profit | 855.38% | -0.93% | |||
| SG&A Expenses | 120.30% | 6.74% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 10.04% | 4.56% | |||
| Operating Income | 693.87% | -1.85% | |||
| Income Before Tax | 727.37% | -3.02% | |||
| Income Tax Expenses | 5,120.66% | -- | |||
| Earnings from Continuing Operations | 714.07% | -2.71% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 714.07% | -2.71% | |||
| EBIT | 693.87% | -1.85% | |||
| EBITDA | 710.76% | -1.83% | |||
| EPS Basic | 711.44% | -1.77% | |||
| Normalized Basic EPS | 724.66% | -2.08% | |||
| EPS Diluted | 686.85% | -1.77% | |||
| Normalized Diluted EPS | 699.96% | -2.08% | |||
| Average Basic Shares Outstanding | 0.43% | 0.92% | |||
| Average Diluted Shares Outstanding | 4.56% | 0.92% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||